ViewRay Aktsia

ViewRay EBITDA

EBITDA (kasum enne intresse, makse, amortisatsiooni ja amortisatsiooni) ettevõttest ViewRay (VRAYQ) seisuga 14. aug 2026 on −103,96 M USD. Eelmisel aastal oli EBITDA (kasum enne intresse, makse, amortisatsiooni ja amortisatsiooni) −105,82 M USD — muutus −1,76% (kõrgem).

EBITDA

−103,96 MUSD

YoY

−1,76%

Viimati uuendatud:

EBITDA (kasum enne intresse, makse, amortisatsiooni ja amortisatsiooni) ettevõttest ViewRay on 2026 −103,96 M USD. EBITDA (kasum enne intresse, makse, amortisatsiooni ja amortisatsiooni) ettevõttest ViewRay oli 2025 −105,82 M USD. See väheneb −1,76% kõrgem võrreldes eelmise aastaga.
Access this data via the Eulerpool API

ViewRay Aktsiate analüüs

Mida ViewRay teeb? ViewRay Inc. is an American medical technology company based in Cleveland, Ohio. It was founded in 2004 by Ivor Jankovic and specializes in the manufacturing of radiation therapy devices. The history of ViewRay begins with the idea of developing innovative technology to treat cancer patients more effectively and gently. In 2005, the company entered into an agreement with the Cleveland Clinic Lerner Research Institute to conduct research on a novel magnetic resonance-guided radiation therapy machine. The research project was led by James F. Dempsey, Chair of the Department of Radiation Oncology at the Cleveland Clinic. In 2009, the first magnetic resonance-guided radiation therapy system was delivered and implemented at the Cleveland Clinic. ViewRay's business model is based on the development and manufacturing of innovative medical devices aimed at making the treatment of cancer patients more effective and gentle. The company focuses on combining magnetic resonance imaging (MRI) and radiation therapy to ensure more precise and safer treatment. ViewRay offers various products, including the MRIdian-Linac system, an advanced radiation therapy device that utilizes MRI technology to provide real-time images of the tumor during radiation. This allows for precise targeting of the tumor while sparing the surrounding tissue. The system also offers the ability to sync radiation therapy with the patient's breathing cycle, further improving the accuracy and effectiveness of the treatment. In addition to the MRIdian-Linac system, ViewRay also offers the MRIdian-MRI system, which is solely dedicated to imaging. The MRIdian-MRI is a diagnostic instrument that allows for better visualization of tissue and tumor studies. The system uses the same MRI technology as the MRIdian-Linac to generate radiation-free images. ViewRay has also specialized in the development of software tools that assist doctors in better planning and monitoring radiation therapy. This includes the RayCare Oncology Information System, which provides a comprehensive workflow and management platform, as well as the RayStation Treatment Planning Software, which enables more precise radiation therapy planning. In terms of market reach, ViewRay has a global presence. The company has a strong presence in North America, Europe, and Asia, and works closely with leading research institutes and hospitals to evaluate and improve the effectiveness and efficiency of its technologies. Overall, ViewRay has developed an innovative and unique portfolio of products and solutions that improve radiation therapy and increase accuracy and safety for patients and doctors. The company is a leader in the development of MRI-guided radiation therapy systems and is expected to continue playing a significant role in the medical technology industry in the future. ViewRay on üks populaarsemaid ettevõtteid Eulpoolist.

Sageli esitatud küsimused ViewRay aktsia kohta

ViewRay EBITDA (kasum enne intresse, makse, amortisatsiooni ja amortisatsiooni) on 2026. aastal −103,96 M USD.

EBITDA (kasum enne intresse, makse, amortisatsiooni ja amortisatsiooni) ettevõttest ViewRay muutus −105,82 M USD-st −103,96 M USD-ks, mis vastab −1,76% muutusele. Väärtus on kõrgem kui eelmisel aastal.

Eulpoolist leiate EBITDA (kasum enne intresse, makse, amortisatsiooni ja amortisatsiooni) ViewRay täieliku ajaloolise arengu alates 2006. aastast – koos aastate väärtustega, graafikutega ja üksikasjalike analüüsidega.

EBITDA mõõdab operatiivset sooritust enne finantsstruktuuri, maksustamiskeskkonna ja mitterahalist amortisatsioonimaksude mõju.

EBITDA = EBIT + amortisatsioon ja amortisatsioon

EBITDA (kasum enne intresse, makse, amortisatsiooni ja amortisatsiooni) USD on investorite jaoks määrav tegur. Selle näitaja muutused võivad signaliseerida põhialuste paranemist või halvenemist, mõjutades otseselt aktsia hinda. Eulpoolis saate EBITDA (kasum enne intresse, makse, amortisatsiooni ja amortisatsiooni) ViewRay ajaloolist arengut ja reaalajas andmeid jälgida.

Access this data via the Eulerpool API

Kasumi- ja kahjumiaruanne — ViewRay

Kõik finantsnäitajad — ViewRay